Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation
NCT ID: NCT05651464
Last Updated: 2022-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
42 participants
INTERVENTIONAL
2023-01-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• does application of vancomycine prior to ECMO liberation have an impact of bloodstream infections?
Participants will get 1 dose of vancomycine I.V. (15-20 mg per kgKG) prior to liberation of ECMO.
Researchers will compare this interventional group to a group without antibiotic prophylaxis.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention: Prophylactic antibiotic treatment
Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Vancomycine
Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Control Arm: No prophylactic antibiotic treatment
Control group - no intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vancomycine
Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECMO-Therapy
Exclusion Criteria
* fever \>38,5°C
* pregnancy
* antibiotic treatment with Vancomycine, Linezolid, Daptomycin or Tygacil on the day of liberation
* prior adverse events after application of Vancomycine
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universität des Saarlandes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Philipp Lepper
Deputy Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philipp M Lepper, MD
Role: PRINCIPAL_INVESTIGATOR
Saarland University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Saarland
Homburg, Saarland, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PL002
Identifier Type: -
Identifier Source: org_study_id